RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:57:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -93.83900M | -88.67900M | -61.98300M | -52.80700M | -43.02100M |
| Minority interest | - | - | - | - | - |
| Net income | -93.86700M | -88.69600M | -62.13100M | -56.60400M | -43.02100M |
| Selling general administrative | 27.02M | 24.70M | 20.94M | 17.64M | 18.41M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | 3.00M | - | 3.50M |
| Reconciled depreciation | 0.51M | 0.50M | 0.35M | 0.10M | 0.15M |
| Ebit | -87.56900M | -85.10700M | -60.22500M | -51.70300M | -41.98200M |
| Ebitda | -88.58700M | -65.59100M | -59.87400M | -43.90300M | -41.82700M |
| Depreciation and amortization | -1.01800M | 19.52M | 0.35M | 7.80M | 0.15M |
| Non operating income net other | -2.27700M | - | 0.58M | - | - |
| Operating income | -87.56900M | -85.10700M | -59.87400M | -51.70300M | -45.88500M |
| Other operating expenses | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M |
| Interest expense | 3.99M | 3.64M | 2.69M | 2.15M | 1.04M |
| Tax provision | 0.03M | 0.02M | 0.15M | - | - |
| Interest income | 0.22M | 0.01000M | 0.27M | 1.20M | 0.81M |
| Net interest income | -3.77400M | -3.63200M | -2.41500M | -0.95000M | -0.23000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.03M | 0.02M | 0.15M | 3.80M | 3.90M |
| Total revenue | 0.00000M | 0.00000M | 3.00M | 0.00000M | 3.50M |
| Total operating expenses | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | -6.27000M | -3.57200M | -2.10900M | -1.10400M | -0.08500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -93.86700M | -88.69600M | -62.13100M | -52.80700M | -43.02100M |
| Net income applicable to common shares | -96.41300M | -102.63900M | -62.13100M | -53.39900M | -36.30700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 147.26M | 155.59M | 117.18M | 122.87M | 160.70M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.05M | 5.81M | 5.34M | 3.68M | 1.10M |
| Total liab | 96.16M | 81.53M | 52.76M | 50.07M | 31.48M |
| Total stockholder equity | 51.10M | 74.05M | 64.41M | 72.80M | 129.22M |
| Deferred long term liab | - | 23.13M | - | - | - |
| Other current liab | 12.82M | 12.03M | 7.87M | 8.02M | 6.46M |
| Common stock | 0.17M | 0.12M | 0.03M | 0.02M | 0.02M |
| Capital stock | 0.17M | 0.12M | 0.03M | 0.02M | 0.02M |
| Retained earnings | -477.90500M | -376.73800M | -282.87100M | -194.17500M | -132.04400M |
| Other liab | - | 23.30M | 0.83M | 0.46M | 0.02M |
| Good will | 17.35M | 17.35M | 17.35M | 27.11M | 27.11M |
| Other assets | 0.00000M | 1.23M | 1.72M | 11.22M | 1.95M |
| Cash | 99.47M | 121.72M | 81.79M | 78.71M | 126.18M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 22.86M | 22.32M | 14.02M | 11.95M | 9.45M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -41.18500M | -83.29800M | -42.00200M | -40.26000M | -103.27100M |
| Short term debt | 1.10M | 2.51M | 1.87M | 0.79M | 0.90M |
| Short long term debt | - | 1.31M | 0.80M | - | - |
| Short long term debt total | 58.28M | 38.42M | 39.78M | 38.45M | 22.91M |
| Other stockholder equity | 528.96M | 450.79M | 347.37M | 267.08M | 100.67M |
| Property plant equipment | - | 1.10M | 10.22M | 9.20M | 2.36M |
| Total current assets | 122.08M | 128.68M | 87.88M | 83.31M | 129.28M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 56.70M | 47.06M | 45.69M | 102.11M |
| Short term investments | 15.00M | - | - | - | - |
| Net receivables | 0.56M | 1.15M | 0.75M | 0.92M | 2.00M |
| Long term debt | 54.57M | 32.30M | 33.14M | 33.18M | 20.10M |
| Inventory | - | - | -0.74700M | - | - |
| Accounts payable | 8.95M | 7.78M | 4.28M | 3.14M | 2.09M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.11900M | -0.11900M | -0.11900M | -0.11900M | -0.11900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.12M | - | 0.02M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -376.73800M | - | -194.17500M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.65M | 1.23M | 1.72M | 3.26M | 1.95M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 25.18M | 26.91M | 29.30M | 39.56M | 31.42M |
| Capital lease obligations | 3.71M | 4.80M | 5.85M | 5.27M | 2.82M |
| Long term debt total | - | - | - | - | 20.10M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.10300M | -0.61500M | -1.36200M | 27.23M | -0.03400M |
| Change to liabilities | 7.23M | 1.17M | 1.03M | -2.75200M | 1.31M |
| Total cashflows from investing activities | -0.10300M | -0.61500M | -1.36200M | 27.23M | 27.23M |
| Net borrowings | -0.79500M | - | 12.39M | 0.48M | 3.53M |
| Total cash from financing activities | 117.23M | 74.25M | 12.39M | 140.66M | -4.53100M |
| Change to operating activities | 5.74M | -1.49800M | -5.09400M | -0.48400M | 1.83M |
| Net income | -93.86700M | -88.69600M | -62.13100M | -52.80700M | -43.02100M |
| Change in cash | 39.92M | 2.41M | -47.38400M | 119.59M | -45.75400M |
| Begin period cash flow | 83.11M | 80.70M | 128.09M | 8.50M | 77.15M |
| End period cash flow | 123.03M | 83.11M | 80.70M | 128.09M | 31.39M |
| Total cash from operating activities | -77.10200M | -70.90500M | -58.81800M | -48.05500M | -40.90300M |
| Issuance of capital stock | 122.63M | 75.98M | 0.00000M | 139.39M | 0.00000M |
| Depreciation | 0.51M | 0.50M | 0.35M | 0.10M | 0.15M |
| Other cashflows from investing activities | -0.10300M | -0.61500M | -1.36200M | 1.00M | 1.00M |
| Dividends paid | - | 13.94M | - | -19.95200M | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | -1.65500M | - | - |
| Sale purchase of stock | 0.21M | -2.00000M | -0.27700M | 19.95M | 0.00000M |
| Other cashflows from financing activities | -4.60600M | 0.26M | 12.95M | 10.64M | 0.14M |
| Change to netincome | 6.15M | 19.29M | 6.49M | 7.19M | 4.47M |
| Capital expenditures | 0.10M | 0.61M | 1.36M | 0.17M | 0.03M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | 2.87M | - | -5.29500M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 40.02M | - | -47.78600M | - | - |
| Change in working capital | 5.74M | -1.49800M | -4.06300M | -3.23600M | -4.46100M |
| Stock based compensation | 5.20M | 6.18M | 5.43M | 2.05M | 5.62M |
| Other non cash items | 5.32M | 19.29M | 7.38M | 7.99M | 0.80M |
| Free cash flow | -77.20500M | -71.52000M | -60.18000M | -48.22900M | -40.93700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals Inc |
-0.0255 3.98% | 0.62 | - | - | 53.87 | 4.39 | 50.06 | -1.7732 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
61 North Beacon Street, Boston, MA, United States, 02134
| Name | Title | Year Born |
|---|---|---|
| Dr. Paula Ragan Ph.D. | Founder, CEO, Pres, Sec. & Director | 1971 |
| Mr. Adam S. Mostafa | CFO, Treasurer & Assistant Sec. | 1980 |
| Dr. Murray W. Stewart M.D. | Interim Chief Medical Officer & Director | 1961 |
| Dr. Richard Peters M.D., Ph.D. | Founder | 1963 |
| Dr. Renato T. Skerlj Ph.D. | Founder | NA |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corp. Advisory Board | 1971 |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer | 1961 |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer | 1964 |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | VP of Investor Relations & Corp. Communications | NA |
| Dr. Robert David Arbeit | Sr. VP of Clinical Devel. and Translational Research | 1948 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...